Halliburton Co
Change company Symbol lookup
Select an option...
HAL Halliburton Co
DPZ Domino's Pizza Inc
CLOEF Cloetta AB
CHH Choice Hotels International Inc
PRAC Productivity Technologies Corp
BAC Bank of America Corp
USAK USA Truck Inc
BABA Alibaba Group Holding Ltd
CTL Centurylink Inc

Energy : Energy Equipment & Services | Mid Cap Value
Company profile

Halliburton Company provides services and products to the upstream oil and natural gas industry throughout the lifecycle of the reservoir, from locating hydrocarbons and managing geological data, to drilling and formation evaluation, well construction and completion, and optimizing production throughout the life of the field. It operates through two segments: the Completion and Production segment, and the Drilling and Evaluation segment. The Completion and Production segment delivers cementing, stimulation, intervention, pressure control, specialty chemicals, artificial lift and completion services. The Drilling and Evaluation segment provides field and reservoir modeling, drilling, evaluation and wellbore placement solutions that enable customers to model, measure, drill and optimize their well construction activities. It serves national and independent oil and natural gas companies. As of December 31, 2016, it had conducted business in approximately 70 countries around the world.

Closing Price
Day's Change
-0.19 (-0.79%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Aslan stock pares its big gain after announcing stock offering

1:34 pm ET December 2, 2019 (MarketWatch)

Shares of Aslan Pharmaceuticals Ltd. (6497.OT) jumped 42% on heavy volume in afternoon trading, but pared by more than half earlier gains of over 100%, after the biotechnology company took advantage of a more-than 12-fold rally in six days to sell more shares to the public. Trading volume swelled to 12.5 million shares, compared with the full-day average of about 1.6 million shares. The Singapore-based company did not provide details about the size of the public offering of American Depositary Shares (ADS). Aslan said it planned to use the proceeds from the stock offering to help fund clinical development of its ASLAN004 and ASLAN003 potential products, and for general corporate purposes. Earlier Monday, the stock had more than doubled (up as much as 114%) after Aslan provided upbeat data (http://www.marketwatch.com/story/aslan-pharmaceuticals-stock-soars-on-heavy-volume-after-rocketing-nearly-9-fold-the-past-week-2019-12-02) from a study of its atopic dermatitis treatment ASLAN004. The stock has now soared 1,132% since the company announced on Nov. 22 that preclinical data characterized ASLAN003 as a potential treatment for acute myeloid leukemia (AML). The stock has now gained 50.5% year to date, while the iShares Nasdaq Biotechnology ETF (IBB) has advanced 22.7% and the S&P 500 has climbed 24.4%.

-Tomi Kilgore; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

December 02, 2019 13:34 ET (18:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.